Alcaloïdes de Vinca : Questions médicales fréquentes
Nom anglais: Vinca Alkaloids
Descriptor UI:D014748
Tree Number:D03.633.100.496.500.500.681.827
Termes MeSH sélectionnés :
Platelet Count
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca : Questions médicales les plus fréquentes",
"headline": "Alcaloïdes de Vinca : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Alcaloïdes de Vinca : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"url": "https://questionsmedicales.fr/mesh/D046948",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"code": {
"@type": "MedicalCode",
"code": "D046948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vinblastine",
"alternateName": "Vinblastine",
"url": "https://questionsmedicales.fr/mesh/D014747",
"about": {
"@type": "MedicalCondition",
"name": "Vinblastine",
"code": {
"@type": "MedicalCode",
"code": "D014747",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vincamine",
"alternateName": "Vincamine",
"url": "https://questionsmedicales.fr/mesh/D014749",
"about": {
"@type": "MedicalCondition",
"name": "Vincamine",
"code": {
"@type": "MedicalCode",
"code": "D014749",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vincristine",
"alternateName": "Vincristine",
"url": "https://questionsmedicales.fr/mesh/D014750",
"about": {
"@type": "MedicalCondition",
"name": "Vincristine",
"code": {
"@type": "MedicalCode",
"code": "D014750",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827.817"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vindésine",
"alternateName": "Vindesine",
"url": "https://questionsmedicales.fr/mesh/D014751",
"about": {
"@type": "MedicalCondition",
"name": "Vindésine",
"code": {
"@type": "MedicalCode",
"code": "D014751",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827.830"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vinorelbine",
"alternateName": "Vinorelbine",
"url": "https://questionsmedicales.fr/mesh/D000077235",
"about": {
"@type": "MedicalCondition",
"name": "Vinorelbine",
"code": {
"@type": "MedicalCode",
"code": "D000077235",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827.915"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"alternateName": "Vinca Alkaloids",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jaume Bastida",
"url": "https://questionsmedicales.fr/author/Jaume%20Bastida",
"affiliation": {
"@type": "Organization",
"name": "Grup de Productes Naturals, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain."
}
},
{
"@type": "Person",
"name": "Sara Abouzeid",
"url": "https://questionsmedicales.fr/author/Sara%20Abouzeid",
"affiliation": {
"@type": "Organization",
"name": "Institute for Plant Biology, Technische Universität Braunschweig, Mendelssohnsstr. 4, 38106, Braunschweig, Germany; Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt."
}
},
{
"@type": "Person",
"name": "Laura Lewerenz",
"url": "https://questionsmedicales.fr/author/Laura%20Lewerenz",
"affiliation": {
"@type": "Organization",
"name": "Institute for Plant Biology, Technische Universität Braunschweig, Mendelssohnsstr. 4, 38106, Braunschweig, Germany."
}
},
{
"@type": "Person",
"name": "Dirk Selmar",
"url": "https://questionsmedicales.fr/author/Dirk%20Selmar",
"affiliation": {
"@type": "Organization",
"name": "Institute for Plant Biology, Technische Universität Braunschweig, Mendelssohnsstr. 4, 38106, Braunschweig, Germany. Electronic address: d.selmar@tu-bs.de."
}
},
{
"@type": "Person",
"name": "Rudolf Vrabec",
"url": "https://questionsmedicales.fr/author/Rudolf%20Vrabec",
"affiliation": {
"@type": "Organization",
"name": "ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic; Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Effect of iron supplementation on platelet count in adult patients with iron deficiency anemia.",
"datePublished": "2022-09-01",
"url": "https://questionsmedicales.fr/article/36050842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09537104.2022.2091772"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictive Value of Red Blood Cell Distribution Width, Platelet Count to Lymphocyte Count Ratio, and Neutrophil Count to Lymphocyte Count Ratio Values for the Detection of Postoperative Infection in Patients Undergoing Liver Transplantation.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37286416",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.transproceed.2023.05.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Subphenotypes of platelet count trajectories in sepsis from multi-center ICU data.",
"datePublished": "2024-08-30",
"url": "https://questionsmedicales.fr/article/39215039",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-71186-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endoscopic band ligation is safe despite low platelet count and high INR.",
"datePublished": "2023-04-06",
"url": "https://questionsmedicales.fr/article/37024710",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12072-023-10515-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of longitudinal platelet count trajectory with ICU mortality: A multi-cohort study.",
"datePublished": "2022-08-19",
"url": "https://questionsmedicales.fr/article/36059447",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.936662"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Alcaloïdes de Vinca - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Alcaloïdes de Vinca",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Alcaloïdes de Vinca",
"description": "Comment les alcaloïdes de Vinca sont-ils diagnostiqués ?\nQuels tests sont utilisés pour évaluer l'efficacité des alcaloïdes ?\nLes alcaloïdes de Vinca sont-ils utilisés pour tous les types de cancer ?\nComment évaluer les effets secondaires des alcaloïdes ?\nLes tests génétiques sont-ils nécessaires pour les alcaloïdes de Vinca ?",
"url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Platelet+Count&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Alcaloïdes de Vinca",
"description": "Quels sont les effets secondaires courants des alcaloïdes de Vinca ?\nLes alcaloïdes de Vinca causent-ils des douleurs ?\nComment se manifestent les réactions allergiques aux alcaloïdes ?\nLes alcaloïdes de Vinca affectent-ils le système immunitaire ?\nQuels symptômes indiquent une surdose d'alcaloïdes de Vinca ?",
"url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Platelet+Count&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Alcaloïdes de Vinca",
"description": "Comment prévenir les effets secondaires des alcaloïdes de Vinca ?\nY a-t-il des précautions à prendre avant le traitement ?\nLes patients doivent-ils éviter certains aliments ?\nComment gérer le stress pendant le traitement ?\nLes vaccinations sont-elles recommandées avant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Platelet+Count&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Alcaloïdes de Vinca",
"description": "Comment les alcaloïdes de Vinca sont-ils administrés ?\nPeut-on combiner les alcaloïdes de Vinca avec d'autres traitements ?\nQuel est le rôle des alcaloïdes de Vinca dans le traitement du cancer ?\nLes alcaloïdes de Vinca nécessitent-ils une surveillance médicale ?\nQuels médicaments interagissent avec les alcaloïdes de Vinca ?",
"url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Platelet+Count&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Alcaloïdes de Vinca",
"description": "Quelles sont les complications possibles des alcaloïdes de Vinca ?\nLes alcaloïdes de Vinca peuvent-ils causer des problèmes cardiaques ?\nComment gérer une réaction sévère aux alcaloïdes de Vinca ?\nLes alcaloïdes de Vinca peuvent-ils affecter la fertilité ?\nQuelles sont les conséquences d'une surdose d'alcaloïdes de Vinca ?",
"url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Platelet+Count&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Alcaloïdes de Vinca",
"description": "Qui est à risque d'effets secondaires des alcaloïdes de Vinca ?\nLes antécédents médicaux influencent-ils le traitement ?\nLe mode de vie affecte-t-il la réponse au traitement ?\nLes interactions médicamenteuses augmentent-elles les risques ?\nLes femmes enceintes peuvent-elles utiliser des alcaloïdes de Vinca ?",
"url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Platelet+Count&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment les alcaloïdes de Vinca sont-ils diagnostiqués ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont pas diagnostiqués, mais utilisés dans le traitement de cancers comme la leucémie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des alcaloïdes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie sont utilisés pour évaluer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Les alcaloïdes de Vinca sont-ils utilisés pour tous les types de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont principalement utilisés pour des cancers spécifiques comme le lymphome et la leucémie."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des alcaloïdes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont évalués par des examens cliniques et des rapports de symptômes."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils nécessaires pour les alcaloïdes de Vinca ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas nécessairement, mais ils peuvent aider à personnaliser le traitement dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des alcaloïdes de Vinca ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, et neuropathie périphérique."
}
},
{
"@type": "Question",
"name": "Les alcaloïdes de Vinca causent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent provoquer des douleurs neuropathiques en raison de leur toxicité."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les réactions allergiques aux alcaloïdes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les réactions allergiques peuvent se manifester par des éruptions cutanées ou des démangeaisons."
}
},
{
"@type": "Question",
"name": "Les alcaloïdes de Vinca affectent-ils le système immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose d'alcaloïdes de Vinca ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des vomissements sévères et des convulsions."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires des alcaloïdes de Vinca ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hydratation adéquate et des médicaments antiémétiques peuvent aider à prévenir les nausées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des précautions à prendre avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin des allergies et des médicaments en cours est crucial."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas d'aliments spécifiques à éviter, mais une alimentation équilibrée est recommandée."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pendant le traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation et un soutien psychologique peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées avant le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement."
}
},
{
"@type": "Question",
"name": "Comment les alcaloïdes de Vinca sont-ils administrés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par voie intraveineuse dans un cadre hospitalier."
}
},
{
"@type": "Question",
"name": "Peut-on combiner les alcaloïdes de Vinca avec d'autres traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent combinés avec d'autres agents chimiothérapeutiques pour une efficacité accrue."
}
},
{
"@type": "Question",
"name": "Quel est le rôle des alcaloïdes de Vinca dans le traitement du cancer ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils inhibent la division cellulaire, ralentissant la croissance des tumeurs malignes."
}
},
{
"@type": "Question",
"name": "Les alcaloïdes de Vinca nécessitent-ils une surveillance médicale ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière est essentielle pour gérer les effets secondaires et ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments interagissent avec les alcaloïdes de Vinca ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains antibiotiques et anticoagulants peuvent interagir, nécessitant une attention particulière."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des alcaloïdes de Vinca ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des saignements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les alcaloïdes de Vinca peuvent-ils causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner des complications cardiaques, nécessitant une surveillance cardiaque."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction sévère aux alcaloïdes de Vinca ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction sévère nécessite une intervention médicale immédiate et l'arrêt du traitement."
}
},
{
"@type": "Question",
"name": "Les alcaloïdes de Vinca peuvent-ils affecter la fertilité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent avoir un impact sur la fertilité, et des conseils en fertilité peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une surdose d'alcaloïdes de Vinca ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surdose peut entraîner des effets neurologiques graves et nécessite une prise en charge urgente."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires des alcaloïdes de Vinca ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients âgés et ceux avec des antécédents de maladies neurologiques sont plus à risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales peuvent influencer le dosage."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il la réponse au traitement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer la tolérance et l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses augmentent-elles les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent augmenter les effets secondaires et les complications."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles utiliser des alcaloïdes de Vinca ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur utilisation est contre-indiquée pendant la grossesse en raison de risques pour le fœtus."
}
}
]
}
]
}
Iron deficiency anemia (IDA) affects more than 1.2 billion individuals globally. In addition to anemia, reactive thrombocytosis is also a common clinical hematological condition in patients with IDA. ...
The red blood cell distribution width (RDW) value is a simple and fast parameter that shows an elevation in the presence of infectious disease. It is thought that proinflammatory signals cause changes...
We retrospectively investigated 200 patients who underwent liver transplantation (LT) in our center. The study group was 100 patients who underwent LT and developed a postoperative abdominal or cathet...
In our study, we found RDW and NLR parameters to be elevated in correlation with infection in patients who underwent LT (P < .05). Other markers were elevated but not significantly correlated with inf...
These parameters can be simple and effective additional tools to implement in patients suspected of infection. Further prospective studies with larger patient groups and varying infection states are r...
Although thrombocytopenia on admission to the ICU is associated with increased in-hospital mortality in septic patients, the role of longitudinally measured platelet counts, which are dynamically chan...
Prophylactic endoscopic band ligation (EBL) is used to prevent variceal bleeding in patients with liver cirrhosis. The association of thrombocytopenia, high INR (international normalized ratio) and li...
We analyzed real-life data of cirrhotic patients undergoing elective EBL at two large Viennese centers between Q1/2000-Q1/2018. PRB was defined as bleeding occurring within 30 days after EBL....
We included 617 patients undergoing a total of 1178 prophylactic EBL procedures (median 2 per patient). Sixteen (2.6%) of 617 patients experienced PRB after a median of 12.5 (IQR 17.3) days with no di...
EBL is safe and procedure-related bleedings are rare (2.6%) including in patients with thrombocytopenia < 50 G/L or high INR ≥ 1.5. Only high MELD, and especially high bilirubin seem to be linked to a...
Platelet (PLT) engages in immune and inflammatory responses, all of which are related to the prognosis of critically ill patients. Although thrombocytopenia at ICU admission contributes to in-hospital...
We adopted a three-phase, multi-cohort study strategy. Firstly, longitudinal PLT trajectory patterns within the first four ICU days and their associations with 28-day survival were tested in the eICU ...
A total of 35,332 ICU patients were included from three cohorts. Trajectory analysis clustered patients into ascending (AS), stable (ST), or descending (DS) PLT patterns. DS patients with high baselin...
Longitudinal PLT trajectory is a complementary predictor to baseline PLT for patient survival, even in patients without risk of thrombocytopenia. Mortality-GRID could identify patients at high mortali...
To examine the clinical significance of thrombocytosis (platelets > 500 × 10...
We performed a database analysis consisting of patients evaluated at our medical centers with an influenza-like illness between 2009 and 2013. We included paediatric patients and examined the associat...
A total of 5171 children were included in the study cohort (median age 0.8 years; interquartile range, 0.2-1.8; 58% male). Younger age, and not the type of viral infection, was associated with a high ...
In children admitted with an influenza-like illness, a high platelet count is an independent predictor of admission outcomes. Platelet count may be used to improve risk assessment and management decis...
To study the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet count in patients with platinum-sensitive recurrent epithelial ovarian cance...
This was a retrospective study on a database of platinum-sensitive recurrent epithelial ovarian cancer patients who received treatment at HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) betw...
In total, 56 patients were recruited in this study. The median overall survival (OS) and progression-free survival (PFS) were 33 (95%CI 23-43) and 11 (95%CI 8-16) months, respectively. Survival analys...
The NLR, PLR, and platelet count were not associated with both the OS or PFS in patients with PS-ROC. However, the WBC level is an easy, readily available, and economical way to predict survival outco...
The most severe complication after posterior single-segment lumbar interbody fusion and internal fixation (PIFIF) surgery for degenerative lumbar diseases is deep surgical site infection (DSSI). Preop...
A single-center retrospective study was conducted from January 2016 to February 2021 at Xi'an Jiaotong University-Affiliated Honghui Hospital, involving 83 patients who underwent revision surgery afte...
There were no significant differences in baseline demographic characteristics between the two patient groups (P > 0.05). The P/M ratio was 13.54 ± 5.05 in the aseptic revision group, while it was 19.2...
Platelets and their related serum biomarkers are closely associated with DSSI. The P/M ratio can serve as a reliable test for screening DSSI and is worth considering for inclusion in the assessment of...
Klotho is a protein that is closely related to human aging. Soluble Klotho (S-Klotho) is a circulating protein, and its level decreases in response to systemic inflammation. The relationship between t...
Data from individuals who participated in the National Health and Nutrition Examination Survey (NHANES) during the five cycles from 2007 to 2016 were retrieved for analysis. Linear regression, two-pie...
A total of 11,123 participants (5463 men (48.17%)), with an average age of 56.2 years, were included. After full adjustment, the S-Klotho levels of participants in the highest quartile group of PHR (β...
Both the PHR and PC were significantly negatively associated with S-Klotho concentrations, and these associations were nonlinear. There was no significant association between HDL-C and S-Klotho concen...